An efficacy study was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering a second dose was estimated at 94.3 percent. The analysis is based on data collected between February and early May 2021.

The data of the Ministry of Health confirmed that, of those vaccinated with Sputnik V and infected 14 days after their second vaccine dose, 98.6 percent experienced mild symptoms.

Vaccination data indicates high safety of Sputnik V:

• No serious adverse events associated with vaccination;

• No deaths related to the vaccination;

• No cerebral vein thrombosis (CVT) cases after vaccination.

Commenting on data, Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said: “Sputnik V has demonstrated the efficacy of 94.3 percent and high safety confirming the data collected in a number of other countries where it is used to protect the population against coronavirus."

"The Russian vaccine is an important part of Bahrain’s diversified national portfolio. Use of Sputnik V is making a significant contribution in mitigating the spread of coronavirus, resuming normal life and economic activity.”

Meanwhile, Bahrain's Health Minister Gaeqa Saeed Al-Saleh said: “Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain. This vaccine is one of a number of approved vaccines made available free to charge to citizens and residents in the Kingdom."

"Sputnik V continues to play an important role in the kingdom’s ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far," she added. — Bahrain News Agency